Symbol
Alnylam Pharmaceuticals, Inc.
Full name of the company.
MEDICAL-BIOMED/GENETICS
Industry name
DRUGS
Major industry name
Medical
Sector name
$235.74
Current price of the stock
$2M
Trading volume of the stock
$30.1B
Market capitalization of the company
Large Cap
Category of market capitalization
32.56%
Long-term growth mean estimate
4.34
Mean analyst rating
35.76%
Potential price appreciation based on analyst price targets
4.41%
Percentage difference of EPS surprise
-
Dividend change over 1 year
$0.00
Shows the amount of dividend paid
15.27
Total debt to total equity ratio
2.78
Current ratio
82.67%
Gross profit margin
-17.73%
Operating profit margin
-17.73%
Earnings before interest and taxes (EBIT) margin
-
Earnings before interest, taxes, depreciation, and amortization (EBITDA) margin
-32.70%
Pretax profit margin
-14.12%
Net profit margin
-124.86%
Measures profitability relative to shareholders' equity
-124.86%
ROE excluding intangible assets
-1.98%
Measures profitability relative to total assets
-7.67%
Measures profitability relative to invested capital
0.14
Asset turnover ratio
1.31
Inventory turnover ratio
1.46
Receivables turnover ratio
61.50
Average number of days it takes to collect receivables
-108.14
Measures valuation relative to earnings
-72.09
P/E based on future earnings estimates
13.38
Measures valuation relative to sales
454.31
Measures valuation relative to book value
794.54
Measures valuation relative to operating cash flow
-540.44
Measures valuation relative to free cash flow
0
Indicates company's M&A activity
© 2022 - 2025 QuantStrategy.io, Arizet Labs, LLC
